The US Supreme Court has given a potential boost to the biosimilars industry with its ruling in a high-profile case involving the US biotech major Amgen (Nasdaq: AMGN) and Sandoz, the generics division of the Swiss pharma giant Novartis (NOVN: VX).
In a unanimous decision on Monday, the court ruled against Amgen’s argument that biosimilar manufacturers should be forced to delay their 180-day marketing notices until after the US Food and Drug Administration (FDA) had approved their marketing applications.
"As the global leader in biosimilars, it is our responsibility to help eliminate barriers so patients can access more affordable medicine"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze